Odyssey Therapeutics, Inc.
ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases. The company’s current pipeline is centered on precision therapies designed to target disease-driving pathways, with programs spanning small molecules and protein therapeutics. Its research includes candidates aimed at key immune system mechanisms such as RIPK2, SLC15A4, IRAK4, and TNFR2, reflecting a broader strategy to address complex immune-mediated conditions. Odyssey Therapeutics serves the healthcare and biotechnology markets, where it contributes to the development of targeted treatments for patients with significant unmet medical needs. Headquartered in Boston, Massachusetts, Odyssey Therapeutics combines discovery and development capabilities across immunology and related therapeutic areas, positioning itself as a specialized player in modern drug development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
-$697K
▼ -33.5% YoY
Net Income (TTM)
-$165M
▼ -14.9% YoY
Op. Margin
23763.99%
▼ -2391.4pp YoY
ROIC
-438.13%
▼ -111.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$132M
▼ -10.5% YoY
Op. Cash Flow (TTM)
-$132M
▼ -10.2% YoY
Net Debt
-$154M
Net Cash Position
Cash & Equiv.
$181M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ODTX
Held by ETFs
ODTX is in 3 US ETFs. The largest of them, with ODTX's weight in each:
Odyssey Therapeutics (ODTX) in three numbers
- Quality score
- 25/100
- Best check: margin trend, +36631.8pp. Weakest: return on capital, -438.1%.
- Quality
Questions about Odyssey Therapeutics
Is Odyssey Therapeutics a high-quality business?
Odyssey Therapeutics scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is margin trend at +36631.8pp, and its weakest is return on capital at -438.1%. The Quality tab shows every check against its target.
Does Odyssey Therapeutics (ODTX) pay a dividend?
No. Odyssey Therapeutics (ODTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ODTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.